Last reviewed · How we verify
Inflexal V
At a glance
| Generic name | Inflexal V |
|---|---|
| Also known as | Inflexal V influenza vaccine (surface antigen, inactivated, virosome) formulated for the WHO requirements of the 2013-2014 season, each 0.5 mL dose containing:, • 15 µg HA antigen of A/California/7/2009 (H1N1)-like virus, • 15 µg HA antigen of A/Texas/50/2012 (H3N2)-like virus, • 15 µg HA antigen of B/Massachusetts/2/2012-like virus, Inflexal V influenza vaccine (surface antigen, inactivated, virosome) formulated for the WHO requirements of the 2012-2013 season, each 0.5 mL dose containing: |
| Sponsor | Crucell Holland BV |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents (PHASE1, PHASE2)
- Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults (PHASE1)
- Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine (PHASE1)
- Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V (PHASE3)
- Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children (PHASE3)
- Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (PHASE3)
- A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere (PHASE4)
- A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inflexal V CI brief — competitive landscape report
- Inflexal V updates RSS · CI watch RSS
- Crucell Holland BV portfolio CI